Hanall Biopharma (009420) — Net Asset Quality Index
Hanall Biopharma (009420) has a Net Asset Quality Index of 78.1% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of ₩201.82 Billion minus total liabilities of ₩44.17 Billion yields net assets of ₩157.65 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See 009420 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Hanall Biopharma Net Asset Quality Index Over Time (2011–2024)
This chart shows how Hanall Biopharma's Net Asset Quality Index has evolved across 14 annual periods from 2011 to 2024. As of September 2025, the index stands at 78.1%, representing net assets of ₩157.65 Billion against total assets of ₩201.82 Billion KRW. Explore Hanall Biopharma cash flow conversion to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Hanall Biopharma (2011–2024)
The table below presents the year-by-year Net Asset Quality Index for Hanall Biopharma from 2011 to 2024, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see 009420 market cap overview.
| Year | Quality Index | Net Assets (KRW) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 79.1% | ₩168.35 Billion | ₩212.88 Billion | ₩44.53 Billion | ▲ +1.4 pp |
| 2023 | 77.7% | ₩186.22 Billion | ₩239.75 Billion | ₩53.53 Billion | ▼ -1.2 pp |
| 2022 | 78.8% | ₩168.26 Billion | ₩213.45 Billion | ₩45.19 Billion | ▼ -3.5 pp |
| 2021 | 82.4% | ₩163.49 Billion | ₩198.48 Billion | ₩34.99 Billion | ▲ +0.0 pp |
| 2020 | 82.3% | ₩181.27 Billion | ₩220.13 Billion | ₩38.86 Billion | ▲ +9.0 pp |
| 2019 | 73.4% | ₩140.42 Billion | ₩191.38 Billion | ₩50.97 Billion | ▲ +1.3 pp |
| 2018 | 72.0% | ₩116.92 Billion | ₩162.30 Billion | ₩45.39 Billion | ▲ +6.1 pp |
| 2017 | 65.9% | ₩111.20 Billion | ₩168.70 Billion | ₩57.50 Billion | ▼ -17.7 pp |
| 2016 | 83.7% | ₩104.36 Billion | ₩124.73 Billion | ₩20.37 Billion | ▲ +2.4 pp |
| 2015 | 81.3% | ₩95.22 Billion | ₩117.13 Billion | ₩21.91 Billion | ▲ +28.7 pp |
| 2014 | 52.6% | ₩45.81 Billion | ₩87.17 Billion | ₩41.36 Billion | ▼ -8.4 pp |
| 2013 | 60.9% | ₩59.63 Billion | ₩97.85 Billion | ₩38.23 Billion | ▼ -2.4 pp |
| 2012 | 63.3% | ₩78.67 Billion | ₩124.27 Billion | ₩45.60 Billion | ▲ +15.2 pp |
| 2011 | 48.1% | ₩50.70 Billion | ₩105.46 Billion | ₩54.75 Billion | — |